Cannabis Campaigners' Guide News Database result:


After you have finished reading this article you can click here to go back.

UK: GW awaits news on cannabis

The Scotsman

Monday 20 Jun 2005

---

SHARES in GW Pharmaceuticals have halved in value over the past week, after
UK regulators demanded more data on its cannabis-based painkiller Sativex.

The mouthspray - which is supposed to ease the burden of multiple sclerosis
- will now have to wait months before being granted a licence in the UK,
although the drug has already been approved in Canada.

Investors will want today's interim results to reassure that Sativex has a
future in the UK, and confirm that it will not need to tap the market for
extra funds.

Evolution analyst Dr Jonathan Senior expects GW to make an annual loss of
ukp10.8 million, compared with ukp15.7m last time.


 

 

 

After you have finished reading this article you can click here to go back. 




This page was created by the Cannabis Campaigners' Guide.

Feel free to link to this page!